Which Patients on Long-Term Trastuzumab Need Cardiac Monitoring?
Trastuzumab’s product labeling carries a black box warning about the potential for the development of drug-induced cardiomyopathy in patients receiving the biological for breast cancer (BC). However, guidelines are less clear on how to manage patients on continuous trastuzumab for metastatic BC. Read more.
|
Role of Chemotherapy After Local Therapy in Older Women With Triple-Negative BC
Currently, about one-quarter of breast cancers (BCs) are diagnosed in women aged 70 to 84 years. Although older women typically have hormonally responsive disease, about 12% to 17% of BCs in the United States are triple-negative BC. There are limited data about the management of triple-negative BC in older woman. Read more.
|